PMID- 27655330
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 7
IP  - 4
DP  - 2016 Dec
TI  - Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 
      Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.
PG  - 725-742
AB  - INTRODUCTION: The present study aims to evaluate the risk of pancreatic cancer 
      with incretin-based therapy among patients with type 2 diabetes mellitus (T2DM). 
      METHODS: We searched EMBASE, MEDLINE, the Cochrane Central Register of Controlled 
      Trials and ClinicalTrials.gov for eligible studies published up to March 06 2016. 
      This meta-analysis includes all studies reporting adverse events of pancreatic 
      cancer with use of incretin-based therapies compared with placebo or non-incretin 
      anti-diabetic drugs in patients with T2DM. We used fixed-effect model to compare 
      pooled relative risk (RR) with related 95% confidence intervals (CI). RESULTS: A 
      total of 159 randomized trials were identified. Out of these, 135 studies were 
      excluded as pancreatic cancer occurrence had not been included as an end point. 
      The remaining 24 trials enrolling 47,904 participants were further assessed. 
      Overall, no increased risk of pancreatic cancer were detected in association with 
      incretin-based treatment (RR = 0.7, 95% CI 0.37-1.05). The incidence of 
      pancreatic neoplasm was even lower among incretin-based groups than controls 
      (RR = 0.50, 95% CI 0.29-0.87) in trials with duration more than 104 weeks. There 
      was even decreased risk of pancreatic cancer within groups paralleled by 
      incretin-matched placebos (RR = 0.55, 95% CI 0.32-0.93) than by non-incretin 
      anti-diabetic drugs. Neither monotherapy (RR = 0.62, 95% CI 0.38-1.01) nor 
      combination regimen (RR = 0.92, 95% CI 0.45-1.90) of incretin mimetics increased 
      the risk of pancreatic cancer. CONCLUSION: This meta-analysis shows that 
      incretin-based therapies are not associated with increase in the risk of 
      pancreatic cancer. Interestingly, subgroup analyses suggested lower risk of 
      pancreatic cancer in incretin groups than placebo in long-term studies 
      (>104 weeks). Considering the inconsistent results among randomized trials and 
      previous epidemiological investigations, more such studies should be conducted to 
      clarify the existence or non-existence of this association. FUNDING: This work 
      was supported by grants from the National Natural Science Foundation of China 
      (Nos. 81270476 and 81470830).
FAU - Chen, Han
AU  - Chen H
AD  - Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, China.
AD  - First Clinical Medical College of Nanjing Medical University, Nanjing, 210029, 
      China.
FAU - Zhou, Xiaoying
AU  - Zhou X
AD  - Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, China.
AD  - First Clinical Medical College of Nanjing Medical University, Nanjing, 210029, 
      China.
FAU - Chen, Tao
AU  - Chen T
AD  - Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, China.
AD  - First Clinical Medical College of Nanjing Medical University, Nanjing, 210029, 
      China.
FAU - Liu, Bingtuan
AU  - Liu B
AD  - Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, China.
AD  - First Clinical Medical College of Nanjing Medical University, Nanjing, 210029, 
      China.
FAU - Jin, Wujuan
AU  - Jin W
AD  - Department of Gastroenterology, Sir Yifu Hospital Affiliated with Nanjing Medical 
      University, Nanjing, 210029, China.
FAU - Gu, Huiyuan
AU  - Gu H
AD  - Department of Gastroenterology, The First Affiliated Hospital of Soochow 
      University, Suzhou, 215006, China.
FAU - Hong, Tianyuan
AU  - Hong T
AD  - Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, China.
AD  - First Clinical Medical College of Nanjing Medical University, Nanjing, 210029, 
      China.
FAU - Zhang, Guoxin
AU  - Zhang G
AD  - Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, China. guoxinz@njmu.edu.cn.
AD  - First Clinical Medical College of Nanjing Medical University, Nanjing, 210029, 
      China. guoxinz@njmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20160921
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5118236
OTO - NOTNLM
OT  - Anti-diabetic drug
OT  - Incretin-based therapy
OT  - Meta-analysis
OT  - Pancreatic cancer
OT  - Type 2 diabetes
EDAT- 2016/09/23 06:00
MHDA- 2016/09/23 06:01
PMCR- 2016/09/21
CRDT- 2016/09/23 06:00
PHST- 2016/07/30 00:00 [received]
PHST- 2016/09/23 06:00 [pubmed]
PHST- 2016/09/23 06:01 [medline]
PHST- 2016/09/23 06:00 [entrez]
PHST- 2016/09/21 00:00 [pmc-release]
AID - 10.1007/s13300-016-0198-3 [pii]
AID - 198 [pii]
AID - 10.1007/s13300-016-0198-3 [doi]
PST - ppublish
SO  - Diabetes Ther. 2016 Dec;7(4):725-742. doi: 10.1007/s13300-016-0198-3. Epub 2016 
      Sep 21.